ArticleFrontiers in immunology2026
Plasma proteomics reveals the molecular features in rapidly progressive pneumoconiosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rapidly progressive pneumoconiosis (RPP) is an aggressive subtype of pneumoconiosis characterized by persistent pulmonary inflammation, rapidly progressive fibrosis, and early-onset progressive massive fibrosis. However, the systemic molecular alterations of RPP remain unclear. Here, we profiled the plasma proteome to identify candidate proteins associated with RPP, aiming to discover potential peripheral biomarkers for this aggressive phenotype. Methods: Plasma samples from 15 RPP patients and 13 non-RPP controls were analyzed by data-independent acquisition (DIA)-based proteomics. Differential expression analysis, protein-protein interaction network analysis, and random forest machine learning were performed for identifying RPP-associated proteins. Subsequently, the least absolute shrinkage and selection operator (LASSO) regression was applied to prioritize candidate biomarkers, whose associations with lung function were then evaluated using correlation analysis. Finally, the expression levels of these key proteins were validated in an independent cohort and a cell model using western blot and enzyme-linked immunosorbent assay. Results: A total of 74 differentially expressed proteins (DEPs) were identified in RPP compared to non-RPP. These DEPs were predominantly enriched in pathways involving macrophage activation, glycolysis/gluconeogenesis, complement and coagulation cascades, cytoskeletal reorganization, and neutrophil extracellular traps. Through DEPs-based screening, six proteins were identified as key molecules of RPP. Five of them showed significant correlations with lung function. The protein expressions of F11, CSTB, PSMB9, PRB4, and DLAT were validated in an independent cohort and crystalline silica-induced cell model. Conclusions: This study provided a systematic plasma proteomic profiling of RPP, revealed coordinated alterations in immune, metabolic, and coagulation pathways, and identified a prioritized panel of candidate biomarkers for future validation. These findings constituted a foundational resource for elucidating the molecular architecture of RPP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.